Abstract:To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with ΔvpuΔnefSHIV-4 (vaccine-I) followed by ΔvpuSHIVPPC (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4+ T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4+ T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4+ and CD8+ T cells by intracellular IFN-γ staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV89.6P in five of the seven, and SHIVKU in three of the seven animals.

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques (P4503)

Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region.

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

Protection of Macaques with Diverse MHC Genotypes against a Heterologous SIV by Vaccination with a Deglycosylated Live-Attenuated SIV

Induction of Balance and Breadth in the Immune Response is Beneficial for the Control of SIVmac239 Replication in Rhesus Monkeys

Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia

Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques

Specificity and Neutralizing Capacity of Three Monoclonal Antibodies Produced against the Envelope Glycoprotein of Simian Immunodeficiency Virus Isolate 251

Immunologic And Virologic Mechanisms For Partial Protection From Intravenous Challenge By An Integration-Defective Siv Vaccine

Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Envelope-Modified Single-Cycle Simian Immunodeficiency Virus Selectively Enhances Antibody Responses And Partially Protects Against Repeated, Low-Dose Vaginal Challenge

Vaccine Induction of Antibodies Against a Structurally Heterogeneous Site of Immune Pressure Within HIV-1 Envelope Protein Variable Regions 1 and 2

Development of Antibodies with Broad Neutralization Specificities Against HIV-1 after Long Term SHIV Infection in Macaques

Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines

HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D gene

Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Local Antibody Production and Concentration on the Path of Virus Entry

Antibodies That Neutralize SIV(mac)251 in T Lymphocytes Cause Interruption of the Viral Life Cycle in Macrophages by Preventing Nuclear Import of Viral DNA.

Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.